Clinical trials: Hodgkin Lymphoma
Peripheral T-Cell Lymphoma
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4.
- Trial name
- NCT01611142
- Testing
- KW-0761 (mogamulizumab)
- Where
- 15 sites in Denmark, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Non Hodgkin's Lymphoma
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.
- Trial name
- NCT01789723
- Testing
- Fusilev, Folotyn
- Sponsor
- Acrotech Biopharma Inc.
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment.
- Trial name
- ExoReBLy (NCT03985696)
- Testing
- blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Lymphoma, B-Cell, Large B-cell Lymphoma
Relmacabtagene Autoleucel in Hematologic Malignancies
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
- Conditions
- Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT06142188
- Testing
- Relmacabtagene Autoleucel
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT06427213
- Testing
- Zanubrutinib,Obinutuzumab, Zanubrutinib and R-BAC
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Diffuse, Large B-Cell, Lymphoma
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
The use of R-CHOP, given every two weeks, will be associated with improvements in response rate, and progression-free survival, when compared to R-CHOP given every three weeks.
- Trial name
- NCT00599170
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Southern California
Mantle Cell Lymphoma, Lymphoma, Mantle Cell
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
This study will evaluate the safety and effectiveness of an experimental cancer vaccine for mantle cell lymphoma a form of cancer of the white blood cells called lymphocytes.
- Trial name
- NCT00005780
- Testing
- EPOCH-R, GM-CSF, Idiotype vaccine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment.
- Conditions
- CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01729806
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
This study is a Randomized Phase II Study to Compare Efficacy of CHOP versus Fractionated ICED in Transplant-eligible Patients with Previously Untreated Peripheral T-cell Lymphoma.
- Trial name
- NCT02445404
- Testing
- CHOP, fractionated ICED
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Samsung Medical Center
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Trial name
- NCT01254578
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back…
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- NCT03739814
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Where
- 285 sites in United States, Puerto Rico
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma
Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
The purpose of this study is to describe the therapeutic practices and the prognosis of patients with relapsed or refractory peripheral T-cell lymphoma in Japan
- Trial name
- NCT06422247
- Testing
- Systemic therapy
- Where
- Japan
- Volunteers
- 307 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin Lymphoma, Adult, T Cell Lymphoma
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
HSP-CAR30 is a cell suspension of genetically modified T-cells to express a second generation (4-1BBz) chimeric antigen receptor (CAR) directed against CD30.
- Trial name
- NCT04653649
- Testing
- HSP-CAR30
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
B-Cell Leukemia, B-Cell Lymphoma
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Clinical studies of CD19 CAR-T cells in the treatment of blood and lymphatic system tumors have achieved unprecedented successes.
- Trial name
- NCT03098355
- Testing
- 4SCAR19/22 T cells, Interleukin-2
- Where
- China
- Sponsor
- Zhujiang Hospital
Leukemia, Lymphoma
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly…
- Trial name
- NCT00005626
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Carcinomas, Disease, Hodgkin
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion.
- Conditions
- Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
- Trial name
- NCT01026415
- Testing
- brentuximab vedotin, rifampin, midazolam
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Seagen Inc.
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT05432635
- Testing
- Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
MB-CART20.1 Lymphoma
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- NCT03664635
- Testing
- MB-CART20.1
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Miltenyi Biomedicine GmbH
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.